Skip to content

Coming to Terms with your Term Sheet

Google Video

Loading...
Loading...

Coming to Terms with your Term Sheet

Coming to Terms
with your Term Sheets
qed@qb3 - UCB
Friday, October 2, 2009
12:00 to 1:00 pm
Stanley Hall Room 621


Term Sheets are the kernel around which you build a critical licensing or partnering transaction.  They are meant to capture key terms -- sometimes with intentional vagueness.  

We will explore both business and legal aspects of Term Sheet negotiations, including how to use Term Sheets to focus discussions and shape a signable deal.  Among other topics, we will explore when to move from talk to Term Sheet, which terms to include (and which to leave out!), how to distinguish between "must have" and "nice to have" terms, and the benefits and perils of ambiguity.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=190304  

Thomas E. Duley is of counsel in Morgan Lewis' Business andFinance Practice. Mr. Duley has more than 10 years of experience in life sciences transactions and intellectual property litigation matters. He has negotiated, drafted, and managed a variety of intellectual property
transactions for life sciences companies, including collaboration
agreements between biotechnology and pharmaceutical companies, licensing agreements with commercial businesses and academicinstitutions, supply and manufacturing agreements, and asset purchases and sales involving drug products and manufacturing facilities. He has
overseen real estate and construction contracts, and guided and implemented formal contracting policies in compliance with Sarbanes-
Oxley regulations. Mr. Duley received his J.D. from UC Davis and a Master of Architecture degree from UCLA.

 

Gilbert R. Mintz, Ph.D. is President of GRM Associates, a biotechnology business development, licensing and strategic planning consulting firm. He specializes in building early-stage companies by focusing their strategic planning and licensing activities, and raising money through venture capitalists. His 25-plus years in the biotechnology industry include executive level business development roles and general and laboratory management. He has negotiated and closed over 400 deals for various clients involving technology platforms, corporate and academic collaborations; in/out licensing of late-stage products for partnerships worldwide; served as the President and CEO, Director of an early-stage cancer company; and provided transactional and strategic planning advice to numerous pre-IPO biotechnology companies. He received his Ph.D. from Washington University (St. Louis) and was a postdoc at Johns Hopkins University.

This email was sent to morgan@luminogenics.com by douglas.crawford@ucsf.edu

 

 

Luminogenics is a resource with interests in systems of technology commercialization in the life sciences. Included here is a directory of hundreds of biotech incubators, research parks, and associations.



Powered by Drupal, an open source content management system
AdaptiveThemes